CD19 and mantle cell lymphoma: And evaluation of these novel CARs in vitro and in xenograft models using CRISPR-mediated CD19- MCL cell lines showed favorable results in avoiding CD19 antigen escape, reported in previous CD19 CAR T-cell therapies of B-cell lymphomas [121].